Go Pro
NASDAQ:REVB

Revelation Biosciences Q4 2025 Earnings Report

Revelation Biosciences logo
$1.10 +0.01 (+0.92%)
Closing price 08/24/2026 03:58 PM Eastern
Extended Trading
$1.10 0.00 (0.00%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revelation Biosciences EPS Results

Actual EPS
-$1.65
Consensus EPS
-$1.41
Beat/Miss
Missed by -$0.24
One Year Ago EPS
N/A

Revelation Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Revelation Biosciences Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Thursday, February 26, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Revelation Biosciences' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Revelation Biosciences Earnings Headlines

Equities Analysts Set Expectations for REVB Q3 Earnings
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
REVB Poised for Big Year
See More Revelation Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Revelation Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Revelation Biosciences and other key companies, straight to your email.

About Revelation Biosciences

Revelation Biosciences (NASDAQ:REVB), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

View Revelation Biosciences Profile